跳转至内容
Merck
CN

主要文件

查看所有文档

E4876

17α-乙炔基雌二醇

≥98%, Synthetic estrogen, powder

别名:

17α-乙炔基-1,3,5(10)-雌甾三烯-1,17β-二醇, 19-去甲-1,3,5(10),17α-雌甾三烯-20-炔-3,17-二醇, 炔雌醇

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C20H24O2
化学文摘社编号:
57-63-6
分子量:
296.40
NACRES:
NA.77
PubChem Substance ID:
24894585
UNSPSC Code:
12352200
EC Number:
200-342-2
MDL number:
MFCD00003690
Beilstein/REAXYS Number:
2419975
Assay:
≥98%
Form:
powder
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

17α-乙炔基雌二醇, ≥98%

biological source

synthetic

sterility

non-sterile

assay

≥98%

form

powder

mp

182-183 °C (lit.)

solubility

ethanol: 50 mg/mL, clear, colorless to faintly yellow

shipped in

ambient

storage temp.

room temp

SMILES string

[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)C#C)[C@]1([H])CCc4cc(O)ccc24

InChI

1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1

InChI key

BFPYWIDHMRZLRN-SLHNCBLASA-N

Gene Information

human ... ESR1(2099)
rat ... Afp(24177), Esr1(24890), Shbg(24775)

General description

17α-乙炔雌二醇 (EE2) 是一种人工合成的激素，为雌二醇 (E2) 的衍生物。与雌激素替代治疗和暂停哺乳有关。EE2 用于治疗骨质疏松症、更年期和绝经后综合症。也用于治疗绝经后妇女的前列腺癌和乳腺癌。EE2 作为内分泌干扰物 (EDC) 发挥作用。

Application

17α-乙炔雌二醇已被用于研究外源性雌激素和选择性雌激素受体调节剂 (SERM) 在大鼠中的作用。它还被用于增加兔肝脏中低密度脂蛋白 (LDL) 受体的浓度。

Biochem/physiol Actions

17α-炔雌醇是一种口服生物活性合成雌激素，用作口服避孕药。

Still not finding the right product?

Explore all of our products under 17α-乙炔基雌二醇

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Repr. 1A

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
WXBD4408V
WXBD3601V
WXBC9894V
WXBC9372V
WXBC9012V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Huda Omar Ali et al.
PloS one, 11(3), e0152114-e0152114 (2016-03-22)
Oestrogens influence the pathology and development of hormone-sensitive breast cancers. Tissue factor pathway inhibitor (TFPI) has been shown to be associated with breast cancer pathogenesis. Recently, we found TFPI mRNA levels to be significantly reduced by oestrogens in a breast
Admane H Shanthanagouda et al.
PloS one, 9(2), e88165-e88165 (2014-02-14)
In human, a reduction in estrogen has been proposed as one of the key contributing factors for postmenopausal osteoporosis. Rodents are conventional models for studying postmenopausal osteoporosis, but the major limitation is that ovariectomy is needed to mimic the estrogen
Analysis of 17-beta-estradiol and 17-alpha-ethinylestradiol in biological and environmental matrices?a review
Barreiros L, et al.
Microchemical Journal, Devoted to the Application of Microtechniques in All Branches of Science, 126, 243-262 (2016)
查看所有相关文献

全球贸易项目编号

货号GTIN
E4876-100MG04061833604052
E4876-10G04061835512492
E4876-1G04061835556724